Bank Of New York Mellon Corp Nektar Therapeutics Transaction History

Bank Of New York Mellon Corp

$521 Trillion
Q1 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $3.31 Million - $6.98 Million	1,631,395 New	1,631,395 $3.69 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $92,157 - $155,819	30,315 Added 1.79%	1,719,478 $5.5 Million
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $322,005 - $626,742	-101,579 Reduced 5.67%	1,689,163 $6.42 Million
Q1 2022 May 11, 2022	BUY	$4.16 - $13.72 $366,254 - $1.21 Million	88,042 Added 5.17%	1,790,742 $9.65 Million
Q4 2021 Feb 11, 2022	SELL	$10.83 - $18.41 $169,868 - $288,760	-15,685 Reduced 0.91%	1,702,700 $23 Million

Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $134,843 - $194,372	-10,317 Reduced 0.6%	1,718,385 $30.9 Million
Q2 2021 Aug 11, 2021	BUY	$16.52 - $20.4 $109,758 - $135,537	6,644 Added 0.39%	1,728,702 $29.7 Million
Q1 2021 May 13, 2021	SELL	$16.56 - $25.46 $182,408 - $280,441	-11,015 Reduced 0.64%	1,722,058 $34.4 Million
Q4 2020 Feb 09, 2021	SELL	$15.77 - $19.03 $932,464 - $1.13 Million	-59,129 Reduced 3.3%	1,733,073 $29.5 Million
Q3 2020 Nov 12, 2020	SELL	$16.59 - $24.79 $1.09 Million - $1.63 Million	-65,722 Reduced 3.54%	1,792,202 $29.7 Million
Q2 2020 Aug 12, 2020	BUY	$16.86 - $23.44 $968,725 - $1.35 Million	57,457 Added 3.19%	1,857,924 $43 Million
Q1 2020 May 06, 2020	SELL	$14.47 - $27.96 $446,037 - $861,867	-30,825 Reduced 1.68%	1,800,467 $32.1 Million
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $5.49 Million - $8 Million	346,123 Added 23.31%	1,831,292 $39.5 Million
Q3 2019 Nov 07, 2019	BUY	$16.91 - $36.27 $97,790 - $209,749	5,783 Added 0.39%	1,485,169 $27.1 Million
Q2 2019 Aug 12, 2019	BUY	$31.0 - $36.3 $1.09 Million - $1.28 Million	35,176 Added 2.44%	1,479,386 $52.6 Million
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $805,637 - $1.18 Million	25,511 Added 1.8%	1,444,210 $48.5 Million
Q4 2018 Feb 11, 2019	BUY	$30.43 - $56.65 $537,698 - $1 Million	17,670 Added 1.26%	1,418,699 $46.6 Million
Q3 2018 Nov 09, 2018	BUY	$46.46 - $68.49 $11.2 Million - $16.5 Million	241,111 Added 20.79%	1,401,029 $0
Q2 2018 Aug 06, 2018	SELL	$46.25 - $104.45 $5.95 Million - $13.4 Million	-128,650 Reduced 9.98%	1,159,918 $56.6 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $39.4 Million - $74.4 Million	-686,290 Reduced 34.75%	1,288,568 $137 Million
Q4 2017 Feb 09, 2018	BUY	$23.02 - $60.5 $45.5 Million - $119 Million	1,974,858	1,974,858 $118 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

Deep Track Capital, LP Greenwich, CT

18.4M
Shares

$21.5 Million
0.57% of portfolio
Vanguard Group Inc Valley Forge, PA

12M
Shares

$14.1 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

7.57M
Shares

$8.86 Million
0.02% of portfolio
Primecap Management CO Pasadena, CA

6.97M
Shares

$8.15 Million
0.0% of portfolio
Black Rock Inc. New York, NY

5.88M
Shares

$6.88 Million
0.0% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account